Co-Diagnostics, Inc. to CEO to Deliver Keynote Address at 2023 MarketsandMarkets Conference in London, England

Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its CEO, Dwight Egan, will deliver the keynote presentation on the Co-Dx PCR Home™ testing platform at the 4th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference on March 23, 2023, in London. The company will also host a booth at the event. The Co-Dx PCR Home™ platform is currently undergoing clinical evaluations subject to FDA review and is not yet available for sale. This conference aims to bring together experts in the field of diagnostic research.

Positive

• CEO Dwight Egan will present on the Co-Dx PCR Home™ platform, highlighting innovation.
• Participation in a significant industry conference, boosting visibility and networking opportunities.

Negative

• The Co-Dx PCR Home™ platform is not currently available for sale, indicating potential market delay.
• The platform is still subject to FDA review, which introduces regulatory uncertainties.

SALT LAKE CITY, March 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company CEO will deliver the keynote address at the 4^th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2023, in London, England, where the Company will also be hosting a booth.

Dwight Egan, CEO of Co-Diagnostics, will be delivering the keynote presentation on the Company's upcoming Co-Dx PCR Home™ testing platform at 9:10 am local time on March 23. Co-Dx recently announced the initiation of clinical evaluations for this at-home/POCT real-time PCR platform, which is subject to FDA review and is not currently for sale.

The MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference is expected to bring academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical and biotechnology companies together to address the challenges and future directions in diagnostic research. To learn more about the event, including registration details, please visit here.

Attendees interested in learning more about the Company and its products, including its upcoming Co-Dx PCR Home platform, are invited to visit Booth EX-4.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-ceo-to-deliver-keynote-address-at-2023-marketsandmarkets-conference-in-london-england-301775743.html

SOURCE Co-Diagnostics

FAQ

When is Co-Diagnostics' CEO presenting at the MarketsandMarkets conference?

Dwight Egan, CEO of Co-Diagnostics, will present on March 23, 2023, at 9:10 am local time.

What is the focus of the Co-Dx PCR Home™ platform?

The Co-Dx PCR Home™ platform focuses on at-home and point-of-care real-time PCR testing.

Is the Co-Dx PCR Home™ platform currently for sale?

No, the Co-Dx PCR Home™ platform is undergoing clinical evaluations and is not available for sale yet.

Where is the 2023 MarketsandMarkets conference being held?

The conference is being held in London, England, on March 23-24, 2023.

What opportunities does the conference provide for Co-Diagnostics?

The conference provides opportunities for networking with academicians, researchers, and industry professionals.